Curevac Nv Stock Today

CVAC Stock  USD 3.01  0.02  0.66%   

Performance

Weak

 
Weak
 
Strong

Odds Of Distress

Below Average

 
High
 
Low
CureVac NV is trading at 3.01 as of the 17th of March 2025, a 0.66 percent down since the beginning of the trading day. The stock's open price was 3.03. CureVac NV has about a 34 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
14th of August 2020
Category
Healthcare
Classification
Health Care
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. Curevac NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 224.34 M outstanding shares of which 3.74 M shares are currently shorted by private and institutional investors with about 6.1 trading days to cover. More on CureVac NV

Moving against CureVac Stock

  0.63KRYS Krystal BiotechPairCorr
  0.53IVA Inventiva SaPairCorr
  0.53PBH Prestige Brand HoldingsPairCorr
  0.35LLY Eli LillyPairCorr
  0.35MLYS Mineralys Therapeutics, TrendingPairCorr
  0.31EWTX Edgewise TherapeuticsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

CureVac Stock Highlights

ESG Sustainability
Environmental
Governance
Social
MD CEOMD MBA
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.09230.0784
Fairly Up
Slightly volatile
Total Current Liabilities184.1 M214.3 M
Fairly Down
Slightly volatile
Non Current Liabilities Total150.8 M76.4 M
Way Up
Slightly volatile
Total Assets838.7 M906.5 M
Significantly Down
Slightly volatile
Total Current Assets645.8 M550.1 M
Fairly Up
Slightly volatile
Debt Levels
CureVac NV can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CureVac NV's financial leverage. It provides some insight into what part of CureVac NV's total assets is financed by creditors.
Liquidity
CureVac NV currently holds 41.82 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. CureVac NV has a current ratio of 3.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about CureVac NV's use of debt, we should always consider it together with its cash and equity.

Investments

(58.34 Million)
CureVac NV (CVAC) is traded on NASDAQ Exchange in USA. It is located in Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076 and employs 999 people. CureVac NV is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 675.26 M. CureVac NV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 224.34 M outstanding shares of which 3.74 M shares are currently shorted by private and institutional investors with about 6.1 trading days to cover. CureVac NV currently holds about 540.87 M in cash with (267.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.85.
Check CureVac NV Probability Of Bankruptcy
Ownership Allocation
CureVac NV holds a total of 224.34 Million outstanding shares. CureVac NV retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CureVac Ownership Details

CureVac Stock Institutional Holders

InstituionRecorded OnShares
Bnp Paribas Arbitrage, Sa2024-12-31
171.7 K
Deutsche Bank Ag2024-12-31
169.9 K
Freestone Capital Holdings, Llc2024-12-31
144.1 K
Legal & General Group Plc2024-12-31
114.8 K
Two Sigma Investments Llc2024-12-31
114.7 K
Susquehanna International Group, Llp2024-12-31
97.9 K
Morgan Stanley - Brokerage Accounts2024-12-31
97.3 K
Pictet Asset Manangement Sa2024-12-31
95.4 K
Dekabank Deutsche Girozentrale2024-12-31
85.6 K
Millennium Management Llc2024-12-31
1.6 M
Bill & Melinda Gates Foundation2024-09-30
1.6 M
View CureVac NV Diagnostics

CureVac NV Historical Income Statement

At present, CureVac NV's Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 15.6 M, whereas Depreciation And Amortization is forecasted to decline to about 20.3 M. View More Fundamentals

CureVac Stock Against Markets

CureVac NV Corporate Management

When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.51
Revenue Per Share
0.294
Quarterly Revenue Growth
0.905
Return On Assets
(0.25)
Return On Equity
(0.54)
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.